«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

32卷

期数:

2026年01期

页码:

39-44

栏目:

肿瘤疾病专题

出版日期:

2026-01-20

文章信息/Info

Title:

Expression and clinical significance of USP21 and TMEM33 in prostate cancer

文章编号:

1006-8147(2026)01-0039-06

作者:

赵朋; 杨拓; 刘鹏; 王金铸; 张晓光

（天津市南开医院泌尿外科，天津 300100）

Author(s):

ZHAO Peng;  YANG Tuo;  LIU Peng;  WANG Jinzhu;  ZHANG Xiaoguang

（Department of Urology， Tianjin Nankai Hospital， Tianjin 300100， China）

关键词:

前列腺癌; 泛素特异性蛋白酶21; 跨膜蛋白33; 生物标志物

Keywords:

prostate cancer;  ubiquitin-specific peptidase 21;  transmembrane protein 33;  biomarker

分类号:

R737.25

DOI:

10.20135/j.issn.1006-8147.2026.01.0039

文献标志码:

A

摘要:

目的：分析泛素特异性蛋白酶21（USP21）与跨膜蛋白33（TMEM33）在前列腺癌组织中的表达特征及其临床意义。方法：采用回顾性研究纳入天津市南开医院2014年1月—2023年1月经病理确诊的前列腺癌病例68例（石蜡包埋组织样本）作为观察组，同期收治的良性前列腺增生患者组织样本20例作为对照。采用免疫组化技术检测两组样本中USP21和TMEM33蛋白表达水平，结合临床病理参数和生存数据进行统计学分析。通过Spearman相关分析评估两蛋白表达关联性，并建立Cox比例风险模型筛选预后相关独立因素。结果：前列腺增生患者中USP21、TMEM33阳性表达率显著低于前列腺癌组织（χ2=11.664、 8.395，均P<0.05）；USP21与TMEM33的阳性表达率在高Gleason评分、临床分期Ⅲ~Ⅳ期及伴有淋巴结转移的前列腺癌组织中显著升高（均P<0.05）。Spearman 相关分析结果显示，USP21和TMEM33表达水平呈正相关（r=0.319，P<0.05）。USP21和TMEM33阳性的患者5年无病生存期低于阴性表达者（χ2=4.246，P=0.039； χ2=12.551， P<0.001，均P<0.05）。Cox回归模型分析显示，USP21（RR=6.743，95%CI：1.698~26.783）和 TMEM33 阳性（RR=2.189，95%CI：0.005~8.809）、高Gleason评分（RR=23.826，95%CI：2.320~24.467）、淋巴结转移（RR=5.996，95%CI：1.825~9.706）、高TNM 分期（RR=3.981，95%CI：1.904~8.320）可作为预测前列腺癌预后的独立危险因素（均P<0.05）。结论：USP21与TMEM33在前列腺癌组织中呈高表达，且与前列腺癌患者的临床病理特征及预后密切相关，可作为诊断前列腺癌以及预测患者预后的评估指标。

Abstract:

Objective： To investigate the expression patterns and clinical significance of ubiquitin-specific protease 21 （USP21） and transmembrane protein 33 （TMEM33） in prostate cancer tissues. Methods： This study employed a retrospective design， enrolling 68 pathologically confirmed prostate cancer cases （paraffin-embedded tissue samples） from the Tianjin Nankai Hospital from January 2014 to January 2023， with 20 matched benign prostatic hyperplasia （BPH） tissue samples as controls. Immunohistochemistry （IHC） was utilized to detect USP21 and TMEM33 protein expression levels in both groups. Statistical analyses were performed in conjunction with clinicopathological parameters and survival data. Spearman correlation analysis was applied to evaluate the association between the two protein expressions， and Cox proportional hazards models were established to identify independent prognostic factors. Results： The positive expression rates of USP21 and TMEM33 in benign prostatic hyperplasia tissues were significantly lower than those in prostate cancer tissues （χ2=11.664， 8.395， both P<0.05）. The positive expression rates of USP21 and TMEM33 were significantly increased in prostate cancer tissues with a high Gleason score， advanced clinical stage Ⅲ-Ⅳ， and lymph node metastasis （all P< 0.05）. Spearman correlation analysis revealed a positive correlation between USP21 and TMEM33 expression levels （r=0.319， P<0.05）. Patients with positive expression of USP21 and TMEM33 proteins had a significantly lower 5-year disease-free survival than those with negative expression （χ2=4.246， P=0.039； χ2=12.551， P<0.001， both P<0.05）. Cox regression analysis revealed that positive expression of USP21（RR=6.743， 95%CI：1.698-26.783） and TMEM33 （RR=2.189， 95% CI： 0.005-8.809）， high Gleason score （RR=23.826， 95% CI： 2.320-24.467）， lymph node metastasis （RR=5.996， 95% CI： 1.825-9.706）， and high TNM stage （RR=3.981， 95% CI： 1.904-8.320） could be identified as independent risk factors for predicting the prognosis of prostate cancer. Conclusion： USP21 and TMEM33 are highly expressed in prostate cancer tissues， closely linked to patients′ clinicopathological features and prognosis， and can serve as biomarkers for diagnosis and prognostic assessment.

参考文献/References:

[1] BERGENGREN O，PEKALA K R，MATSOUKAS K，et al． 2022 update on prostate cancer epidemiology and risk factors-a systematic review[J]． Eur Urol， 2023，84（2）：191-206．
[2] GUO Q， SHI D， LIN L， et al. De-ubiquitinating enzymes USP21 regulate MAPK1 expression by binding to transcription factor GATA3 to regulate tumor growth and cell stemness of gastric cancer[J]. Front Cell Dev Biol， 2021，9（6）：641981
[3] ZHOU P， SONG T， SUN C， et al. USP21 upregulation in cholangiocarcinoma promotes cell proliferation and migration in a deubiquitinase-dependent manner[J]. Asia Pac J Clin Oncol，2021，17（6）：471-477.
[4] ZHANG Q X， CHEN Z X， TANG Q K， et al. USP21 promotes selfrenewal and tumorigenicity of mesenchymal glioblastoma stem cells by deubiquitinating and stabilizing FOXD1[J]. Cell Death Dis， 2022， 13（8）： 712.
[5] ZHANG J Y， LU Q B ， PANG H G，et al. MiR-103a-3p aggravates renal cell carcinoma by targeting TMEM33[J]. Am J Transl Res，2021，13（11）：12694-12703.
[6] CHEN H X，ZHAO X，LI Y Q ，et al. High expression of TMEM33 predicts poor prognosis and promotes cell proliferation in cervical cancer[J]. Front Genet，2022，13（3）： 908807.
[7] XIA C F， DONG X S， LI H， et al. Cancer statistics in China and United States， 2022： profiles， trends， and determinants[J]. Chin Med J （Engl）， 2022， 135（5）： 584-590.
[8] VANDEN BROECK T，VANDEN BERGH RCN，BRIERS E，et a1．Biochemical recurrence in prostate cancer：the European Association of Urology Prostate Cancer guidelines panel recommendations[J]． Eur urol Focus，2020，6（2）：231-234.
[9] WU Y， GUO Y， WANG Q. USP21 accelerates the proliferation and glycolysis of esophageal cancer cells by regulating the STAT3/FOXO1 pathway[J]. Tissue Cell， 2022，79（9）：101916.
[10] PENG F， XU J， CUI B， et al. Oncogenic AURKA-enhanced N（6）-methyladenosine modification increases DROSHA mRNA stability to transactivate STC1 in breast cancer stem-like cells[J]. Cell Res， 2021，31（3）：345-361.
[11] JIANG W N，LIU L，WANG M，et al.KLF15 suppresses stemness of pancreatic cancer by decreasing USP21-mediated Nanog stability[J]. Cell Mol Life Sci，2024， 81（1）：417.
[12] SHIN J H， KIM M J， KIM J Y，et al. USP21-EGFR signaling axis is functionally implicated in metastatic colorectal cancer[J]. Cell Death Disc，2024，10（1）：492.
[13] NIE H H， YU Y L， WANG F，et al. Comprehensive analysis of the relationship between ubiquitin-specifc protease 21（USP21） and prognosis， tumor microenvironment infltration， and therapy response in colorectal cancer[J]. Cancer Immunol Immunother，2024， 73（8）：156.
[14] XU X， CHEN Y， SHAO S Y， et al. USP21 deubiquitinates and stabilizes HSP90 and ENO1 to promote aerobic glycolysis and proliferation in cholangiocarcinoma[J]. Int J Biol Sci， 2024， 20（4）： 1492-1508.
[15] YANG S， YAN H， WU Y， et al. Deubiquitination and stabilization of PD-L1 by USP21[J]. Am J Transl Res， 2021，13（11）：12763-12774.
[16] PEREZ C M，FELTY Q. Molecular basis of the association between transcription regulators nuclear respiratory factor 1 and inhibitor of DNA binding protein 3 and the development of microvascular lesions[J]. Microvasc Res，2022，141（2）：104337.
[17] CHEN H， ZHAO X， LI Y， et al. High expression of TMEM33 predicts poor prognosis and promotes cell proliferation in cervical cancer[J]. Front Genet，2022， 13（1）：908807.
[18] GHALEHBANDI S，YUZUGULEN J，PRANJOL MZI，et al. The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF[J]. Eur J Pharmacol，2023，949（10）：175586.
[19] DONG J， SHANG S， GAO S J，et al. Effect of RNA interference with TMEM33 expression on cervical cancer cells[J]. Fudan Univ J Med Sci，2023，50（2）：159-165.
[20] ZHANG X，DAI M，LI S，et al. The emerging potential role of p62 in cancer treatment by regulating metabolism[J]. Trends Endocrinol Metab，2023，34（8）：474-488.
[21] LIU F， MA M，GAO A，et al. PKM2-TMEM33 axis regulates lipid homeostasis in cancer cells by controlling SCAP stability[J]. EMBO J，2021，40（22）：108065.
[22] ZHANG H， WANG J， YANG J，et al.TMEM33 as a prognostic biomarker of cervical cancer and its correlation with immune infiltration[J]. Mediat Inflammat Vol， 2023，2023（5）：5542181.

相似文献/References:

[1]魏强,齐灿,罗飞,等.转移性去势抵抗性前列腺癌患者多西他赛化疗的预后分析[J].天津医科大学学报,2013,19(05):390.
[2]杨帮东,姜行康,齐 灿,等.尿液中PCA3评分对前列腺癌早期诊断的临床意义[J].天津医科大学学报,2013,19(06):487.
　YANG Bang-dong,JIANG Xing-kang,QI Can,et al.Clinical significance of urinary PCA3 score to diagnose prostate cancer[J].Journal of Tianjin Medical University,2013,19(01):487.
[3]刘利维,刘春雨. MicroRNAs 与前列腺癌的表观遗传学研究进展[J].天津医科大学学报,2014,20(01):74.
[4]王 超,余泉峰,徐 勇,等.经直肠超声造影诊断前列腺癌的临床分析[J].天津医科大学学报,2014,20(05):375.
　WANG Chao,YU Quan-feng,XU Yong,et al.Clinical analysis of contrast-enhanced transrectal ultrasonography for the diagnosis of prostate cancer[J].Journal of Tianjin Medical University,2014,20(01):375.
[5]张晓会,张志宏,徐 勇,等.合并症对局限性或局部晚期前列腺癌患者早期生存的影响[J].天津医科大学学报,2014,20(05):379.
　ZHANG Xiao-hui,ZHANG Zhi-hong,XU Yong,et al. Influence of complications on early survival of patients with localized or locally advanced prostate cancer[J].Journal of Tianjin Medical University,2014,20(01):379.
[6]盛 镔,张 蒙,马鹏德,等.核糖体蛋白L37在前列腺癌中的表达及临床意义[J].天津医科大学学报,2015,21(05):401.
　SHENG Bin,ZHANG Meng,MA Peng-de,et al.Expression of ribosomal protein L37 in prostate cancer and its clinical significance[J].Journal of Tianjin Medical University,2015,21(01):401.
[7]管明秀,周云丽,王 萌,等.TuM2-PK，tPSA，fPSA/tPSA和PSAD对PSA灰区前列腺癌诊断价值的比较[J].天津医科大学学报,2016,22(02):140.
　GUAN Ming-xiu,ZHOU Yun-li,WANG-Meng,et al.Diagnostic implication of TuM2-PK, tPSA, fPSA/tPSA ratio and PSAD for prostate cancer in PSA gray area[J].Journal of Tianjin Medical University,2016,22(01):140.
[8]李 江,张恩龙,赵 阳,等.前列腺癌靶向磁共振成像和光热治疗的实验研究[J].天津医科大学学报,2017,23(02):93.
　LI Jiang,ZHANG En-long,ZHAO Yang,et al.?Experimental research of targeted magnetic resonance imaging and photo thermal therapy for prostate cancer [J].Journal of Tianjin Medical University,2017,23(01):93.
[9]张一然,潘盼,连振鹏,等.磁共振扫描对经直肠超声引导前列腺穿刺活检的影响[J].天津医科大学学报,2017,23(02):99.
　ZHANG Yi-ran,PAN Pan,LIAN Zhen-peng,et al.Effect of magnetic resonance imaging scan on the?transrectal ultrasound?prostate biopsy[J].Journal of Tianjin Medical University,2017,23(01):99.
[10]薄志强,孙桂江,王 丽,等.CtBP2异常表达对前列腺癌PC3细胞增殖效应影响的研究[J].天津医科大学学报,2017,23(02):103.
　BO Zhi-qiang,SUNGui-jiang,WANG Li,et al.Effect of abnormal expression of CtBP2 on the proliferation of prostate cancer cell line PC3[J].Journal of Tianjin Medical University,2017,23(01):103.

备注/Memo

备注/Memo:

基金项目:天津市科技计划项目（20JCQNJC00550）
作者简介:赵朋（1986-），男，主治医师，硕士，研究方向：前列腺癌分子生物学研究；E-mail： zhaopeng198607.27@163.com。

常用功能

更新日期/Last Update: 2026-01-15